Edwards Lifesciences Corp  

(Public, NYSE:EW)   Watch this stock  
Find more results for ew
-0.65 (-0.55%)
After Hours: 117.03 0.00 (0.00%)
Oct 24, 7:15PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 116.92 - 118.56
52 week 72.20 - 121.75
Open 118.24
Vol / Avg. 0.00/1.10M
Mkt cap 24.91B
P/E 48.41
Div/yield     -
EPS 2.42
Shares 212.88M
Beta 0.56
Inst. own 87%
Oct 25, 2016
Q3 2016 Edwards Lifesciences Corp Earnings Call - 5:00PM EDT - Add to calendar
Oct 25, 2016
Q3 2016 Edwards Lifesciences Corp Earnings Release - 4:00PM EDT - Add to calendar
Sep 13, 2016
Edwards Lifesciences Corp at Mitsubishi UFJ Securities Seattle Investor Conference
Sep 8, 2016
Edwards Lifesciences Corp at Wells Fargo Securities Healthcare Conference
Aug 17, 2016
Edwards Lifesciences Corp at Barclays International Medtech Summit
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 16.67% 19.85%
Operating margin 22.26% 24.96%
EBITD margin - 28.44%
Return on average assets 12.85% 13.05%
Return on average equity 21.29% 21.08%
Employees 9,800 -
CDP Score - 82 D


1 Edwards Way
IRVINE, CA 92614-5688
United States - Map
+1-949-2502500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The Company conducts operations around the world and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company's products and technologies it offers to treat advanced cardiovascular disease are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.

Officers and directors

Michael A. Mussallem Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Scott B. Ullem Chief Financial Officer, Corporate Vice President
Age: 49
Bio & Compensation  - Reuters
Donald E. Bobo Jr. Corporate Vice President - Heart Valve Therapy
Age: 54
Bio & Compensation  - Reuters
Catherine M. Szyman Corporate Vice President, Critical Care
Age: 49
Bio & Compensation  - Reuters
Patrick Bruno Verguet Corporate Vice President, Europe, Middle East and Africa
Age: 58
Bio & Compensation  - Reuters
Huimin Wang M.D. Corporate Vice President, Japan, Asia Pacific
Age: 59
Bio & Compensation  - Reuters
Larry L. Wood Corporate Vice President - Transcatheter Heart Valve Therapy
Age: 50
Bio & Compensation  - Reuters
Leslie Stone Heisz Director
Age: 55
Bio & Compensation  - Reuters
Steven R. Loranger Director
Age: 64
Bio & Compensation  - Reuters
Martha H. Marsh Director
Age: 67
Bio & Compensation  - Reuters